Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...
The FDA approved Merck's Keytruda Qlex, a new under-the-skin version of the cancer drug that can be injected in just 1-2 minutes, offering faster and more convenient treatment than traditional IV ...
Merck MRK boasts more than six blockbuster drugs in its portfolio, with the blockbuster PD-L1 inhibitor Keytruda being the key top-line driver. Keytruda, approved for several types of cancer, alone ...
Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results